DOI:
10.1055/s-00000059
Pneumologie
LinksClose Window
References
Yang JC, Wu YL, Schuler M. et al.
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
Lancet Oncol 2015;
16: 141-151
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.